The closing price of Voyager Therapeutics Inc (NASDAQ: VYGR) was $9.44 for the day, up 2.28% from the previous closing price of $9.23. In other words, the price has increased by $+0.21 from its previous closing price. On the day, 529839 shares were traded. VYGR stock price reached its highest trading level at $9.78 during the session, while it also had its lowest trading level at $9.27.
Ratios:
Our analysis of VYGR’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 2.22 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 6.87. For the most recent quarter (mrq), Quick Ratio is recorded 4.96 and its Current Ratio is at 4.96. In the meantime, Its Debt-to-Equity ratio is 0.09 whereas as Long-Term Debt/Eq ratio is at 0.07.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Citigroup on Mar-08-24, initiated with a Buy rating and assigned the stock a target price of $16.
On January 02, 2024, Wells Fargo Upgraded its rating to Overweight which previously was Equal Weight but kept the price unchanged to $14.
On May 10, 2023, Truist started tracking the stock assigning a Buy rating and target price of $18.Truist initiated its Buy rating on May 10, 2023, with a $18 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Feb 21 ’24 when Sandrock Alfred sold 13,033 shares for $7.46 per share. The transaction valued at 97,226 led to the insider holds 334,954 shares of the business.
Swartz Robin sold 3,966 shares of VYGR for $29,547 on Feb 21 ’24. The Chief Operating Officer now owns 118,361 shares after completing the transaction at $7.45 per share. On Feb 21 ’24, another insider, PFREUNDSCHUH PETER P., who serves as the Chief Financial Officer of the company, sold 3,764 shares for $7.46 each. As a result, the insider received 28,079 and left with 175,669 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VYGR now has a Market Capitalization of 501.19M and an Enterprise Value of 290.61M. As of this moment, Voyager’s Price-to-Earnings (P/E) ratio for their current fiscal year is 3.05. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.05 while its Price-to-Book (P/B) ratio in mrq is 1.76. Its current Enterprise Value per Revenue stands at 1.16 whereas that against EBITDA is 2.30.
Stock Price History:
Over the past 52 weeks, VYGR has reached a high of $14.34, while it has fallen to a 52-week low of $6.06. The 50-Day Moving Average of the stock is 8.15, while the 200-Day Moving Average is calculated to be 8.78.
Shares Statistics:
VYGR traded an average of 812.11K shares per day over the past three months and 888.86k shares per day over the past ten days. A total of 44.04M shares are outstanding, with a floating share count of 42.78M. Insiders hold about 21.22% of the company’s shares, while institutions hold 48.33% stake in the company. Shares short for VYGR as of Feb 15, 2024 were 2.15M with a Short Ratio of 2.64, compared to 1.81M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 3.86% and a Short% of Float of 4.59%.
Earnings Estimates
The firm’s stock currently is rated by 6 analysts. On average, analysts expect EPS of -$0.46 for the current quarter, with a high estimate of -$0.4 and a low estimate of -$0.52, while EPS last year was $2.94. The consensus estimate for the next quarter is -$0.52, with high estimates of -$0.35 and low estimates of -$0.67.
Analysts are recommending an EPS of between -$0.6 and -$2.9 for the fiscal current year, implying an average EPS of -$1.89. EPS for the following year is -$1.91, with 6 analysts recommending between $0.15 and -$4.18.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 5 analysts. It ranges from a high estimate of $10M to a low estimate of $5M. As of the current estimate, Voyager Therapeutics Inc’s year-ago sales were $150.48M, an estimated decrease of -94.70% from the year-ago figure.
A total of 7 analysts have provided revenue estimates for VYGR’s current fiscal year. The highest revenue estimate was $90.14M, while the lowest revenue estimate was $5M, resulting in an average revenue estimate of $35.87M. In the same quarter a year ago, actual revenue was $250.01M, down -85.70% from the average estimate.
